1 / 17

APHL Survey HIV Diagnostic Testing Utilization

This survey provides information about the current testing status and utilization of various HIV diagnostic tests, including new EIA screening tests, rapid tests, and nucleic acid amplification tests. It also explores confirmatory testing and challenges in different settings.

greenc
Download Presentation

APHL Survey HIV Diagnostic Testing Utilization

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. APHL SurveyHIV Diagnostic Testing Utilization Barbara G. Werner, PhD MA State Laboratory Institute February 28, 2005

  2. Information about Current Testing Status to Address New Challenges • New EIA screening tests • Expanded use of rapid tests • Additional uses of nucleic acid amplification tests (NAAT) • Confirmatory testing in different settings • The old 9 letter word “algorithm”

  3. Survey Format and Launch • Electronic Survey on APHL LabNet • Content and design input from APHL/CDC HIV Steering Committee • Timeframe: July/August 2004 • Sent to 56 Jurisdictions • PH labs in all states, DC and 5 territories • Limitation: Local/county PH labs not included

  4. Survey Respondents • 49 Responses; overall 88% • 48 States, one territory • 7 No response

  5. Questions about HIV Testing • EIA and Confirmatory Testing • Use of NAAT • Acute infection testing • Incidence surveillance testing • Rapid HIV Testing • CLIA Limited Public Health Use Exception

  6. HIV Screening Tests Utilized (%)* bioMerieux Vironostika HIV-1 63 bioMerieux Viron HIV-1 PLUS O 0 Bio-Rad Gen Sys HIV-1 rLAV 20 Bio-Rad HIV 1/2 Synthetic Peptide 10 Bio-Rad HIV-1/HIV-2 PLUS O 10 Abbott HIVAB HIV-1/2 20 Genetic Systems HIV-2 EIA 18 bioMerieux Oral Viron HIV-1 61 *Percent of responding labs reporting use within past year

  7. EIAs Used for 1o Screening of Sera • bioMerieux Vironostika HIV-1 30 labs* • Bio-Rad Gen. Sys. rLAV 8 • Abbott HIV-1/2 7** • Bio-Rad HIV1/HIV2 Plus O 4 * 2 labs used in tandem --with Genetic Systems rLAV or Bio-Rad HIV-1/2 Synthetic Peptide ** Used as backup in one other state Genetic Systems HIV-2 EIA 9 labs Not necessarily for initial screen

  8. Changes in Use of Screening Tests • 11 indicated that they plan to change to another EIA within next year • Decisions pending validation

  9. Confirmatory Tests Used by Labsfor Serum/Plasma • 34 Bio-Rad Gen Sys HIV-1 Western blot • 11 Calypte Camb Biotech HIV–1 WB • 7 Fluorgnost HIV-1 IFA • 4 in conjunction with Western blot for serum • Only three states planned to switch confirmatory test within year

  10. Testing Oral Fluid Specimens • 30 labs used Oral Vironostika HIV-1 • 28 labs used Orasure HIV-1 WB assay

  11. Nucleic Acid Amplification Testing • 25 labs reported capability • 14 labs currently performing NAAT • 11 for patient monitoring • 3 for acute infection screening • 2 additional states indicated interest in initiating NAAT for acute infection screening within the next year

  12. Seroincidence Testing • At time of survey, 10 states performed incidence testing, as part of CDC or local surveillance efforts • Note: IND for incidence testing using Vironostika EIA to be terminated by CDC

  13. Involvement with HIV Rapid Testing • Approximately one-half reported delivering at least one training course (CDC or own) and 2 additional labs had developed course but had not implemented • With limited follow-up, some labs were involved with confirmatory testing, some with QA responsibilities

  14. CLIA Limited PH Use Exception • Six states reported use of the Exception, allowing multiple labs to operate under a single CLIA certificate • 4 of 6 permit CBOs, etc. to use for HIV rapid testing • On follow up, all 4 provide confirmatory testing and oversight

  15. Conclusions and Challenges • Communication issues • Knowledge of changing assays, incidence testing, etc • Confirmation of new tests with Group O antigens, as well as HIV-2, is an issue as is limited choice for confirmatory tests • Integration of rapid tests • Confirmatory testing • Educational assistance for QA • Likelihood of new or different algorithms in different settings

  16. Efforts to Improve Communication • APHL/CDC HIV Steering Committee • APHL Updates for Members • Electronic and print, including Survey Report for HIV Testing Utilization • APHL ID Committee • Interim Position Statement on Rapid Tests • Presentations/Roundtables • APHL/ASTHO Annual Meetings • HIV Diagnostics Conference • HIV Prevention Conference

  17. Acknowledgments • Anthony Tran, APHL Staff • APHL/CDC HIV Steering Committee • APHL Members

More Related